SUBLOCADE Investments Will Improve Patient And Physician Experience

Key Takeaways

• Commercial investments and label updates for SUBLOCADE are expected to boost revenue growth and enhance patient and physician experience.
  
• Strategic reinvestments and U.S. market stabilization could strengthen revenue projections and profit margins for Indivior.
  
• Intensified competition and legal challenges threaten Indivior's revenue stability and financial flexibility, with potential adverse effects on margins and shareholder returns.

Catalysts

Develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.

• Indivior expects SUBLOCADE net revenue performance to improve in the second half of the year due to commercial investments and important label updates that enhance the patient and physician experience, which should positively impact revenue growth.
  
• The company is making strategic reinvestments of approximately $50 million from gross savings behind SUBLOCADE and its pipeline, while an additional $50 million is allocated to protect profit margins, potentially increasing net margins.
  
• The stabilization of the U.S. long-acting injectable (LAI) category and SUBLOCADE maintaining expected share levels with significant share among experienced dual prescribers could further strengthen revenue projections.
  
• Growth from SUBLOCADE was observed outside the U.S., with an 8% increase to $13 million in net revenue, suggesting international markets could contribute to future revenue growth.
  
• Ongoing initiatives, including the generation of real-world evidence for OPVEE and collaborations for standing orders, could contribute to increased market penetration and revenue for newly launched products.

Indivior Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Indivior's revenue will decrease by 1.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from -5.3% today to 17.8% in 3 years time.
• Analysts expect earnings to reach $201.0 million (and earnings per share of $1.46) by about May 2028, up from $-62.0 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 8.5x on those 2028 earnings, up from -23.4x today. This future PE is lower than the current PE for the GB Pharmaceuticals industry at 26.7x.
• Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.76%, as per the Simply Wall St company report.

Indivior Future Earnings Per Share Growth

Risks

• Intensified competition from generic film providers has led to price erosion in SUBOXONE Film, potentially impacting future revenue and net margins.
  
• The discontinuation of PERSERIS contributed to a decline in total net revenue, suggesting potential challenges in product diversification and revenue generation.
  
• Near-term funding challenges in the justice system have significantly affected SUBLOCADE dispense volumes, which may continue to pressure revenue.
  
• Ongoing litigation and settlement obligations could impact cash flows and financial flexibility, affecting net income and shareholder returns.
  
• The potential for continued pricing pressure in the SUBOXONE Film market, including from new generic entrants, poses risks to revenue stability.

Valuation

• The analysts have a consensus price target of £10.817 for Indivior based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £12.15, and the most bearish reporting a price target of just £9.28.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.1 billion, earnings will come to $201.0 million, and it would be trading on a PE ratio of 8.5x, assuming you use a discount rate of 5.8%.
  
• Given the current share price of £8.72, the analyst price target of £10.82 is 19.3% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.